| Name | Title | Contact Details |
|---|
Headquartered in the heart of Silicon Valley, California, VitalConnect was founded in 2011 with a vision of changing the paradigm of healthcare as we know it by creating a new world of information with predictive data analytics at everyone’s fingertips. VitalConnect provides physicians, nurses and patients with an extraordinary advancement in healthcare. Never before has so much continuous monitoring of vital signs been possible in a single, small—yet powerful—device. By consolidating eight critical vital signs into one wireless biosensor, VitalPatch enables a new view into healthcare, but more importantly it connects all interested parties in a patient’s recovery with each other. VitalConnect is also engaged in numerous partnerships with other leading medical device and pharmaceutical companies. It`s all about helping to bring a new paradigm and vision to fruition and providing the healthcare industry with the predictive data analytics it needs to reduce expenses, increase efficiency, provide better care—and most important of all, to save lives.
Sammons Preston Inc is a Bolingbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Del Norte Clinics is a Yuba City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.